Jixin Ding

Jixin (Jason) Ding is a Principal Scientist at BridgeBio, with a professional trajectory that includes a role as a Sr. Scientist at the same company since January 2020. Previously, Jixin served as a Research Scientist at Bristol-Myers Squibb from December 2018 to January 2020, and held a Research Scientist position at Indiana University School of Medicine for a decade, where collaborations focused on cancer drug development and research project design. Earlier experiences include conducting pre-clinical studies targeting PI3K-Akt/Notch and Stat3/Notch pathways at Indiana University, and investigating AKT signaling and its partners in diabetes and cancer during postdoctoral research at Tufts Medical Center and Harvard Medical School. Jixin earned a PhD in Biochemistry and Molecular Biology from Peking University Health Science Center and a Master of Science in Pharmacology from Shandong University.